PRPF3抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: HepG2 cell lysate, Primary antibody: P09940(PRPF3 Antibody) at dilution 1/2000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09940(PRPF3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The PRPF3 antibody targets the pre-mRNA processing factor 3 (PRPF3), a core component of the spliceosome complex responsible for removing introns during eukaryotic mRNA splicing. PRPF3. also known as HPRP3 or SNRNP3. is essential for spliceosome assembly and catalytic activation, playing a critical role in maintaining RNA splicing fidelity. Structurally, it contains tetratricopeptide repeat (TPR) domains that mediate protein-protein interactions, facilitating its integration into the U4/U6.U5 tri-snRNP particle. Dysregulation of PRPF3 has been linked to retinal degeneration, particularly autosomal dominant retinitis pigmentosa (adRP), where mutations disrupt spliceosome function, leading to photoreceptor cell death. Additionally, PRPF3 overexpression is implicated in cancers, including breast cancer and glioma, where aberrant splicing promotes tumor progression.

PRPF3 antibodies are widely used in research to study spliceosome dynamics, RNA processing mechanisms, and disease pathogenesis. They enable detection of PRPF3 expression and localization via techniques like Western blotting, immunofluorescence, and immunoprecipitation. These tools have been instrumental in elucidating PRPF3’s role in cellular homeostasis, its interaction with other splicing factors (e.g., PRPF4. PRPF31), and its tissue-specific functions. Recent studies also explore PRPF3 as a potential therapeutic target, emphasizing its dual role in genetic and acquired diseases. Validation of PRPF3 antibodies typically involves knockout/knockdown controls to ensure specificity, given the high homology among spliceosomal proteins.